<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01778439</url>
  </required_header>
  <id_info>
    <org_study_id>52M51-002</org_study_id>
    <nct_id>NCT01778439</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors</brief_title>
  <official_title>A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OncoMed Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OncoMed Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects
      with relapsed or refractory solid tumors. Study includes a dose escalation phase and
      expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics,
      biomarkers, and efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile of OMP-52M51 in subjects with relapsed or refractory solid tumors</measure>
    <time_frame>Subjects will be assessed for DLTs from Days 0-29. Adverse events will be reported through 30 days after the last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of OMP-52M51 in subjects with relapsed or refractory solid tumors</measure>
    <time_frame>PK analyses at various time points following the 1st and 2nd doses, immediately pre and post-dose for all subsequent doses at treatment term, every 4 weeks after discontinuation of study drug or 12 weeks</time_frame>
    <description>Apparent half life, AUC, clearance, volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Assessed at baseline, prior to each dose, at treatment termination and every 4 weeks after the discontinuation of the study drug for 12 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Efficacy</measure>
    <time_frame>Evaluation for response will be assessed on day 70 of study and every 8 weeks (or 9 weeks for Q3W schedule) thereafter and will be based on RECIST v1.1.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Relapsed or Refractory Solid Tumors</condition>
  <arm_group>
    <arm_group_label>OMP-52M51</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OMP-52M51</intervention_name>
    <arm_group_label>OMP-52M51</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet all of the following criteria to be eligible for the study:

          1. Age &gt;18 years

          2. ECOG performance status &lt;2 (see Appendix B)

          3. Solid tumor malignancy for which there is no remaining standard therapy or either
             refuse or are not considered to be candidates for any remaining standard therapy.

          4. Must have a tumor that is measurable or evaluable per RECIST v1.1 in the dose
             escalation phase. In the expansion cohort(s), subjects must have measurable disease.

          5. Subjects must have Formalin-Fixed, Paraffin-Embedded (FFPE) tissue available either
             archived or fresh core or punch needle biopsied at study entry (two fresh
             cores/punches preferred whenever possible) for determination of Notch1 pathway
             activation status.

          6. Must have received their last chemotherapy, biologic, radiotherapy, or investigational
             therapy at least 4 weeks prior to enrollment; 6 weeks if the last regimen included
             BCNU or mitomycin C.

          7. Subjects must have normal organ and marrow function as defined below:

               -  Absolute neutrophil count &gt;1500/mL without growth factor support in the past 7
                  days

               -  Platelets &gt;100,000/mL without transfusions in the past 7 days

               -  Total bilirubin &lt;1.5 X institutional upper limit of normal (ULN) (&lt;2X ULN for
                  subjects with Gilbert's syndrome)

               -  AST (SGOT) and ALT (SGPT) &lt;3 X institutional ULN (for subjects with hepatic
                  involvement &lt;5 X institutional ULN but cannot be associated with elevated
                  bilirubin)

               -  PT/INR and aPTT within 1.5 X institutional ULN

               -  Creatinine &lt;1.5 X institutional ULN OR

               -  Creatinine clearance &gt;60 mL/min/1.73 m2 for subjects with creatinine levels above
                  institutional normal

               -  Normal Ejection Fraction (&gt;50%) on ECHO scan or MUGA

          8. Women of childbearing potential must have had a prior hysterectomy or have a negative
             serum pregnancy test and be using adequate contraception prior to study entry and must
             agree to use adequate contraception from study entry through at least 6 months after
             discontinuation of study drug. Men must also agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and
             from study entry through at least 6 months after discontinuation of study drug. Should
             a woman enrolled in the study or a female partner of a man enrolled in the study
             become pregnant or suspect she is pregnant while participating in this study or within
             6 months after discontinuation of study, she should inform the Investigator
             immediately.

          9. Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

        Subjects who meet any of the following criteria will not be eligible for participation in
        the study:

          1. Currently receiving any therapeutic treatment for their malignancy including other
             investigational agents

          2. Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors

          3. Uncontrolled seizure disorder, active neurologic disease, or active CNS involvement
             except for individuals who have previously-treated CNS metastases, are asymptomatic,
             and have no requirement for higher doses of corticosteroids (&gt; prednisone 10mg orally
             per day) or anti-seizure medication for at least 4 weeks prior to first dose of study
             drug.

          4. History of a Grade 4 allergic reaction attributed to humanized or human monoclonal
             antibody therapy

          5. Significant intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          6. Pregnant women or nursing women

          7. Ongoing malignancies or malignancies in remission &lt;3 years other than the malignancies
             included in this trial. Patients with history of known squamous cell skin cancers
             within the past 3 years will not be included in this trial. The following prior
             malignancies are allowable irrespective of when they occurred: in situ carcinoma of
             the cervix, in situ ductal breast cancer, and low-grade local bladder cancer.

          8. Subjects with known HIV infection

          9. Known bleeding disorder or coagulopathy

         10. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels.

         11. Hemoptysis in excess of 2.5 mL(or one-half teaspoon) within 8 weeks of first dose of
             study drug.

         12. Subjects receiving heparin, warfarin, or other similar anticoagulants, except for
             subjects on low molecular weight heparin for DVT/PE prophylaxis. Note: Subjects may be
             receiving low-dose aspirin and/or non-steroidal anti-inflammatory agents.

         13. New York Heart Association Classification II, III, or IV (see Appendix D)

         14. Subjects with poorly controlled blood pressure (defined as systolic blood pressure
             ≥140 mmHg or diastolic blood pressure ≥90 mmHg) that is not responsive to medical
             therapy. Subjects taking antihypertensive medications must be taking ≤2 medications to
             obtain this level of blood pressure control.

             NOTE: Initiation or adjustment of antihypertensive medication(s) is permitted prior to
             study entry.

         15. Subjects with ECG evidence of ischemia or ≥Grade 2 ventricular arrhythmia, subjects
             who have a history of acute myocardial infarction within 6 months, or subjects with
             unstable angina.

         16. Subjects with known clinically significant gastrointestinal disease including, but not
             limited to:

               -  inflammatory bowel disease

               -  active peptic ulcer disease

               -  known intraluminal metastatic lesion(s) with risk of bleeding

               -  history of abdominal fistula, GI perforation, or intra-abdominal abscess within
                  28 days prior to beginning study treatment

         17. Subjects with diarrhea at time of enrollment or have an ongoing requirement for anti
             diarrheal therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, San Francisco/Helen Diller Cancer Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver -RCI-South Tower</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute (KCI)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Oncology Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2013</study_first_submitted>
  <study_first_submitted_qc>January 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2013</study_first_posted>
  <last_update_submitted>February 10, 2017</last_update_submitted>
  <last_update_submitted_qc>February 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>relapsed or refractory</keyword>
  <keyword>solid tumor</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

